<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01028339</url>
  </required_header>
  <id_info>
    <org_study_id>SSH versus mannitol</org_study_id>
    <nct_id>NCT01028339</nct_id>
  </id_info>
  <brief_title>Mannitol vs HS to Treat ICHT After Severe TBI : Comparison on PtiO2 and Microdialysis Values</brief_title>
  <official_title>Mannitol Versus Hypertonic Saline to Treat Intracranial Hypertension After Severe Traumatic Brain Injury : a Comparative Study on the Effects on PtiO2 and Microdialysis Values</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Direction Centrale du Service de Santé des Armées</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Direction Centrale du Service de Santé des Armées</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether hypertonic saline is as much effective as
      mannitol to treat intracranial hypertension after traumatic brain injury and has at least the
      same effects on PtiO2 and cerebral metabolism studied through microdialysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mannitol is frequently used to treat intracranial hypertension after TBI. However, it can be
      deleterious, particularly through hyperdiuresis and risks of hypovolemia. It also needs
      volume compensation and induces logistical problem because of needs of high infused volume to
      achieve osmolar load and avoid hypotension. Finally, some recent studies tend to prove
      superiority of hypertonic saline versus mannitol on the prognosis of TBI. especially through
      modulation of inflammatory reactions mechanisms and apoptosis.

      We would like to prove non inferiority of hypertonic saline versus mannitol after TBI to
      allow its large utilization, especially by field military doctors with specific logistical
      problems. For that, more than the single Intracranial Pressure, we want to study effects of
      HS vs mannitol not only on PtiO2 but also on cerebral microdialysis which gives informations
      on focal metabolism with profiles of ischemia, metabolic crisis, hyperglycolysis (possible
      reflect of neuronal restoration) and normality.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No patients enrolled during 2 years
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of HS versus mannitol on lactate/pyruvate ratio</measure>
    <time_frame>20 min, 40 min, H1, H2, H3 and H4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic profile evaluated thanks to measure of lactate/pyruvate ratio and cerebral glucose</measure>
    <time_frame>20 min, 40 min, H1, H2, H3 and H4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of PtiO2 &gt; 15 mm Hg if PtiO2 was &lt; 15 mm Hg before osmotherapy</measure>
    <time_frame>20 min, 40 min, H1, H2, H3 et H4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICP&lt;20 mm Hg after osmotherapy</measure>
    <time_frame>20 min, 40 min, H1, H2, H3 and H4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interstitial osmolarity</measure>
    <time_frame>20 min, 40 min and H1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necessity of a third line therapy (hypothermia, craniectomy, propofol/barbiturate coma</measure>
    <time_frame>Day after osmotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>After leaving the unit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28th days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glasgow outcome scale</measure>
    <time_frame>6th month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Mannitol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertonic saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertonic saline</intervention_name>
    <description>2 mL/kg of 7.5% hypertonic saline associated to hydroxyethyl starch</description>
    <arm_group_label>Hypertonic saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mannitol</intervention_name>
    <description>Mannitol</description>
    <arm_group_label>Mannitol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe Traumatic brain injury monitored with ICP, PtiO2 and cerebral microdialysis

          -  And ICP&gt; 20 mm Hg needing osmotherapy

          -  And approval of the next of kind

        Exclusion Criteria:

          -  Bilateral fixed dilated pupils

          -  Contra-indication to multimodal neuromonitoring

          -  Previous CNS disease

          -  Contra-indication to HS (cardiac insufficiency,...)

          -  Natremia &gt; 155 mmol/L or osmolarity &gt; 320 mOsm/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry BORET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Direction Centrale du Service de Santé des Armées</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HIA Sainte Anne</name>
      <address>
        <city>Toulon</city>
        <zip>83130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Vialet R, Albanèse J, Thomachot L, Antonini F, Bourgouin A, Alliez B, Martin C. Isovolume hypertonic solutes (sodium chloride or mannitol) in the treatment of refractory posttraumatic intracranial hypertension: 2 mL/kg 7.5% saline is more effective than 2 mL/kg 20% mannitol. Crit Care Med. 2003 Jun;31(6):1683-7.</citation>
    <PMID>12794404</PMID>
  </reference>
  <reference>
    <citation>Sakowitz OW, Stover JF, Sarrafzadeh AS, Unterberg AW, Kiening KL. Effects of mannitol bolus administration on intracranial pressure, cerebral extracellular metabolites, and tissue oxygenation in severely head-injured patients. J Trauma. 2007 Feb;62(2):292-8.</citation>
    <PMID>17297315</PMID>
  </reference>
  <reference>
    <citation>Soustiel JF, Vlodavsky E, Zaaroor M. Relative effects of mannitol and hypertonic saline on calpain activity, apoptosis and polymorphonuclear infiltration in traumatic focal brain injury. Brain Res. 2006 Jul 26;1101(1):136-44. Epub 2006 Jun 19.</citation>
    <PMID>16787640</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2009</study_first_submitted>
  <study_first_submitted_qc>December 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2009</study_first_posted>
  <last_update_submitted>August 7, 2012</last_update_submitted>
  <last_update_submitted_qc>August 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Direction Centrale du Service de Santé des Armées</investigator_affiliation>
    <investigator_full_name>BORET Henry</investigator_full_name>
    <investigator_title>Médecin en chef</investigator_title>
  </responsible_party>
  <keyword>traumatic brain injury</keyword>
  <keyword>PtiO2</keyword>
  <keyword>Cerebral microdialysis</keyword>
  <keyword>Osmotherapy</keyword>
  <keyword>hypertonic saline</keyword>
  <keyword>mannitol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Intracranial Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

